AT-I is a novel TLR4-antagonizing agent (Liu et al., 2016), and it exerted anti-tumor effects on colorectal cancer, bladder cancer and melanoma (Fu et al., 2018; Guo et al., 2019; Li et al., 2020), then we investigated whether it could suppress tumorigenesis in breast cancer via inhibiting TLR4/NF-κB pathway. This evidence concerns the gene NFKB1 and breast cancer.